PharmaFocus Today – Page 141 – media

Hansen Pharmaceuticals obtains drug registration certificate for empagliflozin tablets

Hansen Pharmaceuticals (002412) issued an announcement that the company recently obtained the “Drug Registration Certificate” for the chemical drug “Empagliflozin Tablets” approved and issued by the State Drug Administration. The generic name of the drug is empagliflozin tablets, the dosage form is tablets, the specification is 10mg, and the registration classification is chemical drug Class 4. According to the announcement, the drug registration standard number is YBH32972024, and the approval conclusion shows that the drug meets the registration requirements and has been approved. After obtaining the registration certificate, empagliflozin tablets can be produced and sold domestically, further enriching the company’s product line and helping to enhance market competitiveness. However, the announcement also pointed out that the future production and sales of drugs may be affected by factors such as changes in the market environment, so there is uncertainty in the profit level, and investors need to make decisions carefully. In ...
- Source: drugdu
- 242
- February 13, 2025
China tumor neoantigen mRNA vaccine LK101 has been approved by the FDA for clinical trials

Recently, Beijing Likang Life Science and Technology Co., Ltd. (hereinafter referred to as “Likang Life Science”) independently developed a tumor neoantigen mRNA vaccine product, LK101 injection, which successfully obtained IND (clinical trial application) approval from the U.S. Food and Drug Administration (FDA). This is my country’s first tumor neoantigen mRNA vaccine product approved by the FDA, marking that my country’s innovative strength in the field of tumor immunotherapy has been internationally recognized. Based on the patient’s individual tumor-specific mutations, LK101 injection selects highly immunogenic neoantigens through high-throughput sequencing and artificial intelligence-driven antigen prediction platforms, and uses mRNA technology to encode target antigens, aiming to induce a directional immune response in the body. Compared with traditional treatments, this technology has higher accuracy and safety, and provides new ideas for the treatment of solid tumors. Two years ago, LK101 injection was approved for clinical trials in China and conducted Phase I clinical ...
- Source: drugdu
- 842
- February 13, 2025
Aimi Vaccines Apply for Clinical Trial of mRNA Herpes Zoster Vaccine

On February 11, Aimi Vaccines (06660) issued an announcement that the company recently applied to the Drug Review Center of the China Food and Drug Administration for clinical trials of mRNA herpes zoster vaccines. According to the announcement, the company’s mRNA herpes zoster vaccine showed that specific T cell immunity, IgG antibody titers and membrane antigen fluorescent antibody titers were significantly higher than the commercially available recombinant subunit control vaccine in preclinical animal trials. This shows that the vaccine has obvious advantages in immune protection. In addition, the announcement mentioned that the particularity of the herpes zoster virus makes it latent for life after the initial infection, and T cell-mediated immune protection is the key to controlling viral reactivation. At present, the vaccination rate of herpes zoster vaccine in the target population is only about 0.1%, and the market potential is huge. According to industry consultants, the market size of ...
- Source: drugdu
- 256
- February 13, 2025
The world’s first! Bio-Thera’s “Secukinumab Biosimilar” marketing application has been accepted

On February 8, according to the official website of NMPA, the drug marketing application for “Secukinumab Injection” (BAT2306) submitted by BioAtla was accepted. This is the first secukinumab biosimilar to be submitted for marketing. According to data, the original research secukinumab is a fully human IgG1 monoclonal antibody developed by Novartis that can selectively bind to the cytokine interleukin 17A (IL-17A) and inhibit its interaction with the IL-17 receptor. In December 2014, Secukinumab (trade name: Cosentyx) was first approved for marketing for the treatment of psoriatic arthritis. In March 2019, Secukinumab was approved for marketing in China under the trade name Cosentyx. So far, Novartis’ Secukinumab has been approved for marketing in many countries and regions around the world, including Japan, the European Union, the United States, and China, involving multiple indications such as psoriatic arthritis, psoriasis vulgaris, plaque psoriasis, ankylosing spondylitis, and pustular psoriasis, and all indications have been ...
- Source: drugdu
- 412
- February 13, 2025
Challenge hepatitis B Therapy “Everest”

2%, 80%, 24 times – three figures, hiding the password of China’s hepatitis B treatment drug research and development from weak to strong. Breaking through the 2% survival rate of startups in the industry with a pioneering spirit; Breaking through foreign technology blockade, independent research and development innovation, with a market share of over 80% for individual products; Persisting in doing the ‘difficult but right thing’, single product revenue has increased 24 times in 8 years… Recently, a reporter from Shanghai Securities News visited Xiamen Tebao Bioengineering Co., Ltd. to record the growth story of this Chinese biopharmaceutical enterprise’s’ breakthrough ‘,’ jointing ‘, and’ heading ‘. Innovative drug research and development ‘nine deaths for a lifetime’ Xiamen Biomedical Port, with the sound of waves, inspires people to strive forward. 30 years ago, this was still a sugarcane field, but now it has become one of the national level industrial clusters ...
- Source: drugdu
- 516
- February 12, 2025
Cracking the problem of sky high prices of anti-cancer drugs, new progress has been made in universal CAR-T, and the stock price of Keji Pharmaceutical has surged by 197% in half a year

Keji Pharmaceutical (02171. HK) has made new progress in its universal CAR-T products. On February 10th, Keji Pharmaceutical announced that the first enrolled patient of the universal BCMA CAR-T developed based on the THANK-u Plus platform had a strict sense of complete response (sCR) and minimal residual disease (MRD) negative efficacy evaluation at the 28th day visit. According to its introduction, the patient is a recurrent/refractory multiple myeloma IgA – λ type (R-ISS stage II), who has received first-line combination therapy and autologous hematopoietic stem cell transplantation in the past. After the last treatment, the disease progressed and was included in the clinical trial. This CAR-T product is intended for the treatment of relapsed/refractory multiple myeloma (R/R MM) or relapsed/refractory plasma cell leukemia (R/R PCL). Affected by this news, on February 10th, the stock price of Keji Pharmaceutical rose by more than 12% at one point after opening, and finally ...
- Source: drugdu
- 584
- February 12, 2025
The Wealth Creation Myth of GLP-1 Market Exceeding $50 Billion

GLP-1 drugs have lived up to expectations and delivered an unexpected result in 2024, with a global market size of 51.8 billion US dollars. The two giant single products, Simeglutide and Tilpotide, continue to soar, with strong growth beyond imagination. Starting from 2022, GLP-1 drugs began to show explosive potential, with a market size exceeding the $20 billion threshold that year, followed by nearly $35 billion in revenue in 2023, and now breaking through $50 billion in one fell swoop, achieving a triple leap in three years and aiming to reach $60 billion by 2025. In terms of market share, both Novo Nordisk and Eli Lilly shine brightly, with the former holding a market share of around 58% and the latter occupying the remaining share. The sales of products developed by other GLP-1 players have declined. From a numerical perspective alone, the GLP-1 market is already comparable to the PD ...
- Source: drugdu
- 417
- February 12, 2025
Minimally invasive surgery dark horse changes coach

On February 7th, Intuitive Fosun officially announced that Dr. Liu Qijun has joined the company and taken over as CEO, stationed in the Shanghai office. Since November 15, 2024, when Pan Xiaofeng, the former CEO of Intuitive Fosun, officially retired, this news has caused a “huge uproar” in the medical equipment industry. Since then, it has been uncertain who will replace the new CEO. Finally, three months later, Intuitive Fosun has welcomed a new leader. Newly appointed CEO takes office Robot surgery is hailed as the “third technological revolution” in the field of surgery, marking a new milestone in the development of modern surgery. Although China started relatively late in the field of robotic surgery, the huge demand has driven the rapid development of this technology. In this technological revolution, Intuitive Surgery quickly gained a foothold in the global operating room market with its revolutionary product – the da Vinci ...
- Source: drugdu
- 516
- February 12, 2025
Scan the code to know the “past and present” of the drug. The medical insurance drug consumables traceability information query function is online

February 10 (Reporter Xu Penghang) The reporter learned from the National Medical Insurance Bureau on the 10th that the “Medical Insurance Drug Consumables Traceability Information Query” function of the National Medical Insurance Service Platform APP was officially launched recently. By scanning the drug traceability code on the medicine box, drug buyers can obtain detailed drug sales information and understand the “past and present” of the drug. At present, nearly 33,000 people use this function to query drug sales information every day. The drug traceability code is the only “electronic ID card” for each box of drugs. The traceability code of a box of drugs should only have a record of being scanned and sold once. If it appears repeatedly, there is a possibility of counterfeit drugs, reflux drugs or drugs being sold in exchange. According to reports, after drug buyers register and log in to the National Medical Insurance Service ...
- Source: drugdu
- 279
- February 12, 2025
Jinhe Bio (002688.SZ) ranks second in the number of blue ear vaccine batches issued, and large vaccine products continue to emerge

According to statistics from Xinzhupai, the number of blue ear vaccine batches issued in 2024 will total 412 million, which is basically the same as in 2023. Boehringer ranks first with more than 60 million batches issued. Jinhe Youben, a subsidiary of Jinhe Bio, which has become popular with blue ear inactivated vaccines, has ranked second for two consecutive years, with nearly 40 million batches issued in 2024. Public information shows that Jinhe Bio is based on the animal health industry, and has entered the veterinary biological products business field through external mergers and acquisitions, and has a full layout of the veterinary vaccine sector. There are currently 16 products on the market, and more than 20 products under research and application, with broad development space and strong potential. Among them, the blue ear inactivated vaccine Youlanbao® and blue ear chimeric vaccine Youlantai® launched by Jinhe Bio’s subsidiary Jinhe Youben ...
- Source: drugdu
- 342
- February 12, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.